These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

163 related articles for article (PubMed ID: 33521663)

  • 1. Mavrilimumab for severe COVID-19 - Authors' reply.
    De Luca G; Cavalli G; Campochiaro C; Della-Torre E; Dagna L
    Lancet Rheumatol; 2020 Nov; 2(11):e662-e663. PubMed ID: 33521663
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study.
    Takeuchi T; Tanaka Y; Close D; Godwood A; Wu CY; Saurigny D
    Mod Rheumatol; 2015 Jan; 25(1):21-30. PubMed ID: 24720551
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomised phase IIb study of mavrilimumab, a novel GM-CSF receptor alpha monoclonal antibody, in the treatment of rheumatoid arthritis.
    Burmester GR; McInnes IB; Kremer J; Miranda P; Korkosz M; Vencovsky J; Rubbert-Roth A; Mysler E; Sleeman MA; Godwood A; Sinibaldi D; Guo X; White WI; Wang B; Wu CY; Ryan PC; Close D; Weinblatt ME;
    Ann Rheum Dis; 2017 Jun; 76(6):1020-1030. PubMed ID: 28213566
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nonclinical safety of mavrilimumab, an anti-GMCSF receptor alpha monoclonal antibody, in cynomolgus monkeys: relevance for human safety.
    Ryan PC; Sleeman MA; Rebelatto M; Wang B; Lu H; Chen X; Wu CY; Hinrichs MJ; Roskos L; Towers H; McKeever K; Dixit R
    Toxicol Appl Pharmacol; 2014 Sep; 279(2):230-9. PubMed ID: 24937321
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor α Monoclonal Antibody: Long-Term Safety and Efficacy in Patients With Rheumatoid Arthritis.
    Burmester GR; McInnes IB; Kremer JM; Miranda P; Vencovský J; Godwood A; Albulescu M; Michaels MA; Guo X; Close D; Weinblatt M
    Arthritis Rheumatol; 2018 May; 70(5):679-689. PubMed ID: 29361199
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Randomized Phase IIb Study of Mavrilimumab and Golimumab in Rheumatoid Arthritis.
    Weinblatt ME; McInnes IB; Kremer JM; Miranda P; Vencovsky J; Guo X; White WI; Ryan PC; Godwood A; Albulescu M; Close D; Burmester GR
    Arthritis Rheumatol; 2018 Jan; 70(1):49-59. PubMed ID: 28941039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Blockade of GM-CSF pathway induced sustained suppression of myeloid and T cell activities in rheumatoid arthritis.
    Guo X; Higgs BW; Bay-Jensen AC; Wu Y; Karsdal MA; Kuziora M; Godwood A; Close D; Ryan PC; Roskos LK; White WI
    Rheumatology (Oxford); 2018 Jan; 57(1):175-184. PubMed ID: 29069507
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anakinra for severe forms of COVID-19 - Authors' reply.
    Hayem G; Huet T; Jouveshomme S; Beaussier H; Chatellier G; Mourad JJ
    Lancet Rheumatol; 2020 Oct; 2(10):e587-e588. PubMed ID: 32838321
    [No Abstract]   [Full Text] [Related]  

  • 9. Tocilizumab for severe COVID-19 pneumonia - Authors' reply.
    Guaraldi G; Meschiari M; Milic J; Cozzi-Lepri A; Mussini C
    Lancet Rheumatol; 2020 Nov; 2(11):e660-e661. PubMed ID: 32838326
    [No Abstract]   [Full Text] [Related]  

  • 10. Mavrilimumab for severe COVID-19.
    Pourhoseingholi MA; Shojaee S; Ashtari S
    Lancet Rheumatol; 2020 Nov; 2(11):e662. PubMed ID: 33521662
    [No Abstract]   [Full Text] [Related]  

  • 11. Mavrilimumab for severe COVID-19.
    Khan AR; Soneja M; Tirlangi PK; Wig N
    Lancet Rheumatol; 2020 Nov; 2(11):e661-e662. PubMed ID: 33521661
    [No Abstract]   [Full Text] [Related]  

  • 12. Letter: severe COVID-19 infection and biologic therapies-a cohort study of 7808 patients in France. Authors' reply.
    Taxonera C; Alba C
    Aliment Pharmacol Ther; 2020 Oct; 52(7):1249-1250. PubMed ID: 33016549
    [No Abstract]   [Full Text] [Related]  

  • 13. COVID-19 Vaccine in Children: Where Do We Stand?: Authors' Reply.
    Kasi SG; Shah A
    Indian Pediatr; 2021 Feb; 58(2):195. PubMed ID: 33632967
    [No Abstract]   [Full Text] [Related]  

  • 14. Authors' reply re: Pre-eclampsia-like syndrome induced by severe COVID-19: a prospective observational study.
    Mendoza M; Garcia-Ruiz I; Carreras E; Suy A
    BJOG; 2020 Nov; 127(12):1576-1577. PubMed ID: 32741048
    [No Abstract]   [Full Text] [Related]  

  • 15. Estimating vulnerability to COVID-19 in India - Authors' reply.
    Acharya R; Porwal A
    Lancet Glob Health; 2020 Dec; 8(12):e1467. PubMed ID: 33220209
    [No Abstract]   [Full Text] [Related]  

  • 16. Severe COVID-19 as a virus-independent immunothrombotic process - Authors' reply.
    McGonagle D; Watad A; Bridgewood C
    Lancet Rheumatol; 2022 Mar; 4(3):e173. PubMed ID: 35233541
    [No Abstract]   [Full Text] [Related]  

  • 17. COVID-19 and the difficulty of inferring epidemiological parameters from clinical data - Authors' reply.
    Verity R; Okell L; Dorigatti I; Winskill P; Whittaker C; Walker P; Donnelly C; Ferguson N; Ghani A
    Lancet Infect Dis; 2021 Jan; 21(1):28. PubMed ID: 32473660
    [No Abstract]   [Full Text] [Related]  

  • 18. Authors' reply to: Rivera-Lillo et al. comment on: Early rehabilitation in post-acute COVID-19 patients: data from an Italian COVID-19 rehabilitation unit and proposal of a treatment protocol.
    Curci C; Pisano F; Negrini F; de Sire A
    Eur J Phys Rehabil Med; 2021 Feb; 57(1):172-173. PubMed ID: 32935958
    [No Abstract]   [Full Text] [Related]  

  • 19. Mechanistic modeling of antigen sink effect for mavrilimumab following intravenous administration in patients with rheumatoid arthritis.
    Wang B; Lau YY; Liang M; Vainshtein I; Zusmanovich M; Lu H; Magrini F; Sleeman M; Roskos L
    J Clin Pharmacol; 2012 Aug; 52(8):1150-61. PubMed ID: 21947370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Assessing the importance of interleukin-6 in COVID-19 - Authors' reply.
    Leisman DE; Ronner L; Pinotti R; Taylor MD; Sinha P; Calfee CS; Hirayama AV; Mastroianni F; Turtle CJ; Harhay MO; Legrand M; Deutschman CS
    Lancet Respir Med; 2021 Feb; 9(2):e14-e15. PubMed ID: 33460572
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.